
Over the past few weeks, one "clinical stage" pharma firm after another has seen its stock price rise and plummet on rumors about who has the most likely Ebola vaccine.
I'm not taking you on any wild rides like that. Instead, check out this solid big-cap company that's gearing up for a major Ebola drug trial.